Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | APLNR | P35414 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31085334 | 0.81 | POLB (0.54) | POLBCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL17540952 | 0.81 | ALDH1A1 (0.36) | POLBCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL8776461 | 0.79 | CHRNB2 (0.39) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL21434917 | 0.79 | APLNR (0.52) | POLBAPLNRTP53ALOX15SMN1; SMN2 | |
| SCHEMBL21434918 | 0.79 | APLNR (0.52) | POLBAPLNRTP53ALOX15SMN1; SMN2 | |
| SCHEMBL18883613 | 0.79 | APLNR (0.41) | POLBAPLNRALOX15ALDH1A1 | |
| SCHEMBL16945660 | 0.79 | APLNR (0.41) | POLBAPLNRALOX15ALDH1A1 | |
| SCHEMBL19550863 | 0.79 | APLNR (0.52) | POLBAPLNRTP53ALOX15SMN1; SMN2 | |
| SCHEMBL19550516 | 0.74 | POLB (0.35) | POLBAPLNRALOX15ALDH1A1 | |
| SCHEMBL19550513 | 0.74 | POLB (0.35) | POLBAPLNRALOX15ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040972-B2 | Autotaxin inhibitors and uses thereof | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2021-06-22 | — | — | US | disclosed |
| US-20200354357-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2020-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040972-B2 | Autotaxin inhibitors and uses thereof | ENPP2, SERPINB1, RNASE1 | POLB 1408/4885CHRNB2 3611/4885CHRNA4 4453/4885 |
| US-20200354357-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | ENPP2, SERPINB1, RNASE1 | POLB 1408/4885CHRNB2 3611/4885CHRNA4 4453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.